Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007099718 | Prostate | BPH | neuron death | 98/3107 | 361/18723 | 2.35e-07 | 5.12e-06 | 98 |
GO:190121618 | Prostate | BPH | positive regulation of neuron death | 37/3107 | 97/18723 | 2.88e-07 | 6.16e-06 | 37 |
GO:00075697 | Prostate | BPH | cell aging | 45/3107 | 132/18723 | 7.00e-07 | 1.35e-05 | 45 |
GO:190121418 | Prostate | BPH | regulation of neuron death | 87/3107 | 319/18723 | 8.86e-07 | 1.63e-05 | 87 |
GO:007121410 | Prostate | BPH | cellular response to abiotic stimulus | 89/3107 | 331/18723 | 1.28e-06 | 2.23e-05 | 89 |
GO:010400410 | Prostate | BPH | cellular response to environmental stimulus | 89/3107 | 331/18723 | 1.28e-06 | 2.23e-05 | 89 |
GO:003109810 | Prostate | BPH | stress-activated protein kinase signaling cascade | 70/3107 | 247/18723 | 2.32e-06 | 3.79e-05 | 70 |
GO:005140310 | Prostate | BPH | stress-activated MAPK cascade | 68/3107 | 239/18723 | 2.77e-06 | 4.41e-05 | 68 |
GO:00605377 | Prostate | BPH | muscle tissue development | 100/3107 | 403/18723 | 1.35e-05 | 1.76e-04 | 100 |
GO:00148964 | Prostate | BPH | muscle hypertrophy | 35/3107 | 104/18723 | 1.60e-05 | 2.01e-04 | 35 |
GO:00148973 | Prostate | BPH | striated muscle hypertrophy | 34/3107 | 102/18723 | 2.63e-05 | 3.10e-04 | 34 |
GO:00033004 | Prostate | BPH | cardiac muscle hypertrophy | 33/3107 | 99/18723 | 3.43e-05 | 3.82e-04 | 33 |
GO:000974318 | Prostate | BPH | response to carbohydrate | 67/3107 | 253/18723 | 4.20e-05 | 4.48e-04 | 67 |
GO:005140215 | Prostate | BPH | neuron apoptotic process | 64/3107 | 246/18723 | 1.08e-04 | 9.93e-04 | 64 |
GO:00485888 | Prostate | BPH | developmental cell growth | 61/3107 | 234/18723 | 1.46e-04 | 1.29e-03 | 61 |
GO:00147066 | Prostate | BPH | striated muscle tissue development | 91/3107 | 384/18723 | 1.90e-04 | 1.57e-03 | 91 |
GO:00435239 | Prostate | BPH | regulation of neuron apoptotic process | 55/3107 | 212/18723 | 3.42e-04 | 2.55e-03 | 55 |
GO:00030127 | Prostate | BPH | muscle system process | 103/3107 | 452/18723 | 3.54e-04 | 2.62e-03 | 103 |
GO:00903982 | Prostate | BPH | cellular senescence | 29/3107 | 93/18723 | 3.66e-04 | 2.71e-03 | 29 |
GO:00712604 | Prostate | BPH | cellular response to mechanical stimulus | 26/3107 | 81/18723 | 4.39e-04 | 3.16e-03 | 26 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0401210 | Cervix | CC | ErbB signaling pathway | 28/1267 | 85/8465 | 2.40e-05 | 1.82e-04 | 1.08e-04 | 28 |
hsa0513516 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
hsa051207 | Cervix | CC | Epithelial cell signaling in Helicobacter pylori infection | 24/1267 | 70/8465 | 4.35e-05 | 3.09e-04 | 1.83e-04 | 24 |
hsa04664 | Cervix | CC | Fc epsilon RI signaling pathway | 22/1267 | 68/8465 | 2.35e-04 | 1.31e-03 | 7.77e-04 | 22 |
hsa0491212 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
hsa046686 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa049265 | Cervix | CC | Relaxin signaling pathway | 30/1267 | 129/8465 | 7.92e-03 | 2.56e-02 | 1.51e-02 | 30 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa05132110 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP2K4 | SNV | Missense_Mutation | | c.785G>T | p.Ser262Ile | p.S262I | P45985 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
MAP2K4 | SNV | Missense_Mutation | | c.1187N>C | p.Leu396Pro | p.L396P | P45985 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
MAP2K4 | SNV | Missense_Mutation | | c.850G>A | p.Glu284Lys | p.E284K | P45985 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP2K4 | SNV | Missense_Mutation | | c.1186C>G | p.Leu396Val | p.L396V | P45985 | protein_coding | deleterious(0) | benign(0.306) | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
MAP2K4 | SNV | Missense_Mutation | | c.803C>T | p.Ser268Phe | p.S268F | P45985 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AR-A1AS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP2K4 | SNV | Missense_Mutation | | c.584N>T | p.Ser195Leu | p.S195L | P45985 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MAP2K4 | SNV | Missense_Mutation | | c.433C>T | p.Arg145Trp | p.R145W | P45985 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B6-A0X4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MAP2K4 | SNV | Missense_Mutation | | c.584N>T | p.Ser195Leu | p.S195L | P45985 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
MAP2K4 | SNV | Missense_Mutation | | c.590N>G | p.Asp197Gly | p.D197G | P45985 | protein_coding | deleterious(0.01) | possibly_damaging(0.838) | TCGA-BH-A0EI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP2K4 | SNV | Missense_Mutation | | c.901N>T | p.Val301Phe | p.V301F | P45985 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | TRAMETINIB | TRAMETINIB | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 135652717 | STAUROSPORINE | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | PD 0325901 | | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | | ethanol | ALCOHOL | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | GDC-0973 | COBIMETINIB | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | BAY869766 | | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | AZD6244 | SELUMETINIB | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 178102628 | | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | SELUMETINIB | SELUMETINIB | |
6416 | MAP2K4 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | MEK162 | BINIMETINIB | |